Lord, Abbett & Co
ORIC icon

Lord, Abbett & Co’s Oric Pharmaceuticals ORIC Stock Holding History

Lord, Abbett & Co’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.88M Sell
542,598
-21,655
-4% -$246K 0.02% 409
2025
Q4 		$4.62M Buy
+564,253
New +$6.5M 0.01% 474

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lord, Abbett & Co's ORIC Position: Q1 2026 in Review

Lord, Abbett & Co reduced its Oric Pharmaceuticals (ORIC) stake by 3.8% in Q1 2026, selling an estimated $246K and leaving 542,598 shares worth $6.88M. The position accounts for 0.02% of the portfolio, ranked #409.

Lord, Abbett & Co first reported a position in ORIC in Q4 2025 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Lord, Abbett & Co held 542,598 shares of Oric Pharmaceuticals worth $6.88M as of Q1 2026.
  • Lord, Abbett & Co sold 21,655 Oric Pharmaceuticals shares in Q1 2026, an estimated $246K.
  • Oric Pharmaceuticals made up 0.02% of Lord, Abbett & Co's portfolio in Q1 2026, its #409 holding.
  • Lord, Abbett & Co first reported a position in Oric Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.